SCHEMBL353590

SCHEMBL353590

CC#CC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL11438559 0.88 CA4 (0.38)
SCHEMBL1003846 0.76
Urea SCHEMBL11071285 0.72
SCHEMBL5685592 0.72
SCHEMBL2125754 0.69
SCHEMBL11294277 0.69 LMNA (0.39)
SCHEMBL26114372 0.69
SCHEMBL24159199 0.67
SCHEMBL27257110 0.67
SCHEMBL4778808 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4067354-B1 NOVEL TRIAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DAEWOONG PHARMACEUTICAL CO LTD (KR) 2025-10-22 EP claimed
CN-119894871-A Pyrimidine compounds as kinase inhibitors having biological activity against EGFR mutants 南京爱德程医药科技有限公司 2025-04-25 CN claimed
US-20250093362-A1 HIGH-THROUGHPUT ENGINEERING OF MOLECULAR GLUES FRONTIER MEDICINES CORPORATION 2025-03-20 US claimed
WO-2024156288-A1 DNMT1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS SHANGHAI KYGENT PHARMACEUTICAL CO., LTD (CN) 2024-08-02 WO claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 EP claimed
CN-118139847-A Pyrimidine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient 韩国化学研究院 2024-06-04 CN claimed
WO-2024094064-A1 PYRIMIDINYLAMINOBENZENES FOR TREATING LUNG CANCER WITH DISTANT METASTASIS SUZHOU PUHE BIOPHARMA CO., LTD (CN) 2024-05-10 WO claimed
EP-4359082-A1 HER2 MUTATION INHIBITORS Array BioPharma Inc. (US) 2024-05-01 EP claimed
EP-4330256-A1 PYRIMIDINYLAMINOBENZENES FOR LUNG CANCER TREATMENT Suzhou Puhe Biopharma Co., Ltd. (CN) 2024-03-06 EP claimed
US-20230227458-A1 IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION BIOMEA FUSION, INC. 2023-07-20 US claimed
EP-1790639-B1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2014-03-26 EP claimed
US-7951816-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2011-05-31 US claimed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP claimed
EP-1347974-B1 AMINOTRIAZOLOPYRIDIINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2004-11-03 EP claimed
JP-2003526686-A 2003-09-09 JP claimed
CN-1429126-A Use of cyanoquinolines for treating or inhibiting colonic polyps AMERICAN CYANAMID CO (US) 2003-07-09 CN claimed
EP-1263503-A2 USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS AMERICAN CYANAMID COMPANY (US) 2002-12-11 EP claimed
WO-2001068186-A2 USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS AMERICAN CYANAMID COMPANY (US) 2001-09-20 WO claimed
EP-0973746-A1 SUBSTITUTED 3-CYANO QUINOLINES American Cyanamid Company (US) 2000-01-26 EP claimed
WO-1998043960-A1 SUBSTITUTED 3-CYANO QUINOLINES AMERICAN CYANAMID COMPANY (US) 1998-10-08 WO claimed